Pharmacokinetics
Conditions
Brief summary
The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.
Detailed description
To evaluate the pharmacokinetic characteristics and safety profiles of AG2304 compared with coadministration AG23041 and AG23042 after a single oral dose administration in healthy Korean subjects under fasting conditions.
Interventions
DRUGAG2304
AG2304, Single-dose Oral Administration
DRUGAG23041 and AG23042
AG23041/AG23042, Single-dose Oral Administration
Sponsors
Ahn-Gook Pharmaceuticals Co.,Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* A healthy adults aged 19-65 years at the time of screening * Subjects who are deemed eligible based on the screening tests
Exclusion criteria
* Subjects who have taken the investigational drug within 6 months prior to the first dose * Other exclusions have been applied
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC | Pharmacokinetic plasma samples collected over a 72-hour period | Area under the plasma concentration |
| Cmax | Pharmacokinetic plasma samples collected over a 72-hour period | Peak Plasma Concentration |
Outcome results
None listed